Back to Search
Start Over
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
- Source :
-
European Neurology . Mar2017, Vol. 77 Issue 3/4, p201-210. 10p. 1 Diagram, 7 Charts. - Publication Year :
- 2017
-
Abstract
- Background/Aim: The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ). Methods: Relevant studies were identified by an extensive literature search in Medline, Current Contents and Cochrane databases by 2 independent reviewers using the terms "glioblastoma multiforme/glioblastoma, TMZ, radiation therapy/RT and survival." Results: Results revealed a median survival of 13.41-19 months in the combined treatment group, as opposed to 7.7-17.1 months in the RT-alone group. Progression-free survival (PFS) was also significantly different between the 2 groups (RT + TMZ, 6.3-13 months; RT-alone, 5-7.6 months). While there was no significant difference in the 6-month survival and 6-month PFS rates between the RT + TMZ and RT groups (pooled OR 0.690; p = 0.057 and OR 0.429, p = 0.052, respectively), the 1-year survival and 1-year PFS rates showed significant difference (OR 0.469; p = 0.030 and OR 0.245, p < 0.001, respectively). Conclusions: Concomitant RT + TMZ is more effective and improves the overall survival and PFS in patients with newly diagnosed glioblastoma. [ABSTRACT FROM AUTHOR]
- Subjects :
- *TEMOZOLOMIDE
*GLIOBLASTOMA multiforme
*RADIOTHERAPY
*PATIENTS
Subjects
Details
- Language :
- English
- ISSN :
- 00143022
- Volume :
- 77
- Issue :
- 3/4
- Database :
- Academic Search Index
- Journal :
- European Neurology
- Publication Type :
- Academic Journal
- Accession number :
- 121925049
- Full Text :
- https://doi.org/10.1159/000455842